BACKGROUND: The left ventricles of both rabbits and humans express predominantly beta-myosin heavy chain (MHC). Transgenic (TG) rabbits expressing 40% alpha-MHC are protected against tachycardia-induced cardiomyopathy, but the normal amount of alpha-MHC expressed in humans is only 5% to 7% and its functional importance is questionable. This study was undertaken to identify a myofilament-based mechanism underlying tachycardia-induced cardiomyopathy protection and to extrapolate the impact of MHC isoform variation on myofilament function in human hearts. METHODS AND RESULTS: Papillary muscle strips from TG rabbits expressing 40% (TG40) and 15% alpha-MHC (TG15) and from nontransgenic (NTG) controls expressing approximately 100% beta-MHC (NTG40 and NTG15) were demembranated and calcium activated. Myofilament tension and calcium sensitivity were similar in TGs and respective NTGs. Force-clamp measurements revealed approximately 50% higher power production in TG40 versus NTG40 (P<0.001) and approximately 20% higher power in TG15 versus NTG15 (P<0.05). A characteristic of acto-myosin crossbridge kinetics, the "dip" frequency, was significantly higher in TG40 versus NTG40 (0.70+/-0.04 versus 0.39+/-0.09 Hz, P<0.01) but not in TG15 versus NTG15. The calculated crossbridge time-on was also significantly shorter in TG40 (102.3+/-14.2 ms) versus NTG40 (175.7+/-19.7 ms) but not in TG15 versus NTG15. CONCLUSIONS: The incorporation of 40% alpha-MHC leads to greater myofilament power production and more rapid crossbridge cycling, which facilitate ejection and relengthening during short cycle intervals, and thus protect against tachycardia-induced cardiomyopathy. Our results suggest, however, that, even when compared with the virtual absence of alpha-MHC in the failing heart, the 5% to 7% alpha-MHC content of the normal human heart has little if any functional significance.
BACKGROUND: The left ventricles of both rabbits and humans express predominantly beta-myosin heavy chain (MHC). Transgenic (TG) rabbits expressing 40% alpha-MHC are protected against tachycardia-induced cardiomyopathy, but the normal amount of alpha-MHC expressed in humans is only 5% to 7% and its functional importance is questionable. This study was undertaken to identify a myofilament-based mechanism underlying tachycardia-induced cardiomyopathy protection and to extrapolate the impact of MHC isoform variation on myofilament function in human hearts. METHODS AND RESULTS: Papillary muscle strips from TG rabbits expressing 40% (TG40) and 15% alpha-MHC (TG15) and from nontransgenic (NTG) controls expressing approximately 100% beta-MHC (NTG40 and NTG15) were demembranated and calcium activated. Myofilament tension and calcium sensitivity were similar in TGs and respective NTGs. Force-clamp measurements revealed approximately 50% higher power production in TG40 versus NTG40 (P<0.001) and approximately 20% higher power in TG15 versus NTG15 (P<0.05). A characteristic of acto-myosin crossbridge kinetics, the "dip" frequency, was significantly higher in TG40 versus NTG40 (0.70+/-0.04 versus 0.39+/-0.09 Hz, P<0.01) but not in TG15 versus NTG15. The calculated crossbridge time-on was also significantly shorter in TG40 (102.3+/-14.2 ms) versus NTG40 (175.7+/-19.7 ms) but not in TG15 versus NTG15. CONCLUSIONS: The incorporation of 40% alpha-MHC leads to greater myofilament power production and more rapid crossbridge cycling, which facilitate ejection and relengthening during short cycle intervals, and thus protect against tachycardia-induced cardiomyopathy. Our results suggest, however, that, even when compared with the virtual absence of alpha-MHC in the failing heart, the 5% to 7% alpha-MHC content of the normal human heart has little if any functional significance.
Authors: Teruo Noguchi; Phillip Camp; Shari L Alix; Joseph A Gorga; Kelly J Begin; Bruce J Leavitt; Frank P Ittleman; Norman R Alpert; Martin M LeWinter; Peter VanBuren Journal: J Mol Cell Cardiol Date: 2003-01 Impact factor: 5.000
Authors: L A Mulieri; W Barnes; B J Leavitt; F P Ittleman; M M LeWinter; N R Alpert; D W Maughan Journal: Circ Res Date: 2002-01-11 Impact factor: 17.367
Authors: C Pantos; V Malliopoulou; I Mourouzis; K Sfakianoudis; S Tzeis; P Doumba; C Xinaris; A D Cokkinos; H Carageorgiou; D D Varonos; D V Cokkinos Journal: J Endocrinol Date: 2003-09 Impact factor: 4.286
Authors: Todd J Herron; Eric Devaney; Lakshmi Mundada; Erik Arden; Sharlene Day; Guadalupe Guerrero-Serna; Immanuel Turner; Margaret Westfall; Joseph M Metzger Journal: FASEB J Date: 2009-10-02 Impact factor: 5.191
Authors: Fady I Malik; James J Hartman; Kathleen A Elias; Bradley P Morgan; Hector Rodriguez; Katjusa Brejc; Robert L Anderson; Sandra H Sueoka; Kenneth H Lee; Jeffrey T Finer; Roman Sakowicz; Ramesh Baliga; David R Cox; Marc Garard; Guillermo Godinez; Raja Kawas; Erica Kraynack; David Lenzi; Pu Ping Lu; Alexander Muci; Congrong Niu; Xiangping Qian; Daniel W Pierce; Maria Pokrovskii; Ion Suehiro; Sheila Sylvester; Todd Tochimoto; Corey Valdez; Wenyue Wang; Tatsuo Katori; David A Kass; You-Tang Shen; Stephen F Vatner; David J Morgans Journal: Science Date: 2011-03-18 Impact factor: 47.728
Authors: Cameron Donaldson; Bradley M Palmer; Michael Zile; David W Maughan; John S Ikonomidis; Henk Granzier; Markus Meyer; Peter VanBuren; Martin M LeWinter Journal: Circ Heart Fail Date: 2012-09-26 Impact factor: 8.790
Authors: Sean C Little; Brandon J Biesiadecki; Ahmet Kilic; Robert S D Higgins; Paul M L Janssen; Jonathan P Davis Journal: J Biol Chem Date: 2012-06-20 Impact factor: 5.157
Authors: Michelle M Monasky; Domenico M Taglieri; Marcus Henze; Chad M Warren; Megan S Utter; David G Soergel; Jonathan D Violin; R John Solaro Journal: Am J Physiol Heart Circ Physiol Date: 2013-07-19 Impact factor: 4.733
Authors: Yuan Wang; Bertrand C W Tanner; Andrew T Lombardo; Sarah M Tremble; David W Maughan; Peter Vanburen; Martin M Lewinter; Jeffrey Robbins; Bradley M Palmer Journal: J Mol Cell Cardiol Date: 2012-10-30 Impact factor: 5.000